Tolerability of MDMA in Schizophrenia (TMS)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05770375 |
Recruitment Status :
Not yet recruiting
First Posted : March 15, 2023
Last Update Posted : May 8, 2024
|
Sponsor:
Anya Bershad, MD, PhD
Collaborator:
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Anya Bershad, MD, PhD, University of California, Los Angeles
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Impaired social motivation, or "asociality," is a negative symptom of schizophrenia (SCZ) and a cause of significant functional impairment in the illness. Whereas many symptoms of schizophrenia can be treated with antipsychotic medications, deficits in social motivation persist, leading to significant social disability in patients. There is currently no effective treatment for this symptom of the illness. One promising and unexplored avenue to enhance social motivation in schizophrenia is ± 3,4-methylenedioxymethamphetamine (MDMA). MDMA is a psychostimulant that shares some pharmacological properties with amphetamines, but in addition, has pronounced pro-social effects, increasing the motivation to engage socially. In healthy volunteers, it produces feelings of empathy and closeness with others and increases attention to positive social cues, perhaps partly through its effects on the social bonding hormone, oxytocin. MDMA has shown promise in other psychiatric conditions such as PTSD. Thus, MDMA could offer a unique therapeutic benefit in patients with SCZ who suffer from impaired social motivation. The investigators plan to take the first step in testing MDMA as a treatment for these social deficits by testing the tolerability of the drug in patients with SCZ. This will be an open-label, ascending-dose, within-subject trial in which participants will receive 40mg, 80mg, or 120mg of MDMA. The doses will be administered in ascending order, but doses will be stopped if subjects experience moderate or greater psychotic symptoms at 24 hours. This trial will assess the tolerability of the drug in this population and guide in the selection of a maximum well-tolerated dose for future studies. The primary tolerability measure will be clinician-rated psychotic symptoms (disorganized speech, delusions, hallucinations) collected at 24 hours after MDMA administration. The results of this project will lay the foundation for further investigations of MDMA and other psychoactive compounds as a treatment for debilitating and difficult-to-treat social deficits in schizophrenia. Future studies will examine interactions between the effects of psychoactive compounds and nonpharmacologic psychosocial interventions targeting social symptoms.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Schizophrenia | Drug: MDMA 40mg Drug: MDMA 80mg Drug: MDMA 120mg | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 20 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Intervention Model Description: | Ascending-dose tolerability study |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Tolerability of MDMA in Schizophrenia |
Estimated Study Start Date : | August 1, 2024 |
Estimated Primary Completion Date : | March 2025 |
Estimated Study Completion Date : | March 2026 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Schizophrenia
MedlinePlus related topics:
Schizophrenia
Arm | Intervention/treatment |
---|---|
Experimental: MDMA
Each subject will receive 3 doses of MDMA in ascending order: 40mg, 80mg, 120mg.
|
Drug: MDMA 40mg
MDMA 40mg Drug: MDMA 80mg MDMA 80mg Drug: MDMA 120mg MDMA 120mg |
Primary Outcome Measures :
- Positive and Negative Syndrome Scale for Schizophrenia (PANSS): Disorganized speech. [ Time Frame: 24 hours after each drug session ]The PANSS is a validated 30-item clinician-administered scale assessing symptom severity in SCZ. It is widely used to assess the efficacy of antipsychotic medications. Symptoms are rated from 1 (not present) to 7 (extremely severe). The PANSS will be administered at the first session, before drug administration at each drug session, and 24 hours after each drug session. Our primary tolerability outcome measure will be clinician-rated psychotic symptoms on the three core DSM-V symptoms of psychosis (disorganized speech, delusions, hallucinations) on the PANSS 24 hours after each drug session. This is the item assessing disorganized speech.
- Positive and Negative Syndrome Scale for Schizophrenia (PANSS): Delusions [ Time Frame: 24 hours after each drug session ]The PANSS is a validated 30-item clinician-administered scale assessing symptom severity in SCZ. It is widely used to assess the efficacy of antipsychotic medications. Symptoms are rated from 1 (not present) to 7 (extremely severe). The PANSS will be administered at the first session, before drug administration at each drug session, and 24 hours after each drug session. Our primary tolerability outcome measure will be clinician-rated psychotic symptoms on the three core DSM-V symptoms of psychosis (disorganized speech, delusions, hallucinations) on the PANSS 24 hours after each drug session. This is the item assessing delusions.
- Positive and Negative Syndrome Scale for Schizophrenia (PANSS): Hallucinations [ Time Frame: 24 hours after each drug session ]The PANSS is a validated 30-item clinician-administered scale assessing symptom severity in SCZ. It is widely used to assess the efficacy of antipsychotic medications. Symptoms are rated from 1 (not present) to 7 (extremely severe). The PANSS will be administered at the first session, before drug administration at each drug session, and 24 hours after each drug session. Our primary tolerability outcome measure will be clinician-rated psychotic symptoms on the three core DSM-V symptoms of psychosis (disorganized speech, delusions, hallucinations) on the PANSS 24 hours after each drug session. This is the item assessing hallucinations.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Ages 18-60
- able to understand spoken English sufficiently to comprehend testing procedures
- DSM-5 diagnosis of schizophrenia, based on clinical interview
- clinical stability (i.e., no inpatient hospitalizations for six months prior to enrollment, no changes in medication in for 6 months prior to enrollment)
Exclusion Criteria:
- no history of aggressive or suicidal behavior while psychotic
- no history of IQ less than 70 or developmental disability, based on medical history
- no clinically significant neurological disease (e.g., epilepsy), or cardiovascular condition (e.g. cardiac arrhythmia) based on medical history
- no history of serious head injury (i.e., loss of consciousness longer than 1 hour, neuropsychological sequelae, cognitive rehabilitation treatment after head injury) based on medical history
- no substance or alcohol use disorder in the past six months
- no sedatives or benzodiazepines within 24 hours of testing
- no positive urine toxicology screen or visible intoxication on the day of assessment
- no women who are pregnant or think that they might be pregnant, based on self-report and urine test
- not currently taking SSRIs or SNRIs
- no history of NMS or serotonin syndrome
- No prolongation of the QTc interval on EKG
No Contacts or Locations Provided
Responsible Party: | Anya Bershad, MD, PhD, Principal Investigator, University of California, Los Angeles |
ClinicalTrials.gov Identifier: | NCT05770375 |
Other Study ID Numbers: |
IRB#22-001600 1DP5OD036172-01 ( U.S. NIH Grant/Contract ) |
First Posted: | March 15, 2023 Key Record Dates |
Last Update Posted: | May 8, 2024 |
Last Verified: | May 2024 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Additional relevant MeSH terms:
Schizophrenia Schizophrenia Spectrum and Other Psychotic Disorders Mental Disorders N-Methyl-3,4-methylenedioxyamphetamine Hallucinogens Physiological Effects of Drugs Psychotropic Drugs |
Serotonin Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Adrenergic Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Adrenergic Agents |